证券代码：603882 证券简称：金域医学 公告编号：2024-042 广州金域医学检验集团股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 注：截至本次股东大会股权登记日（2024 年 5 月 13 日），广州金域医学检验集团股份有限 公司（以下简称"公司"）总股本为 468,771,275 股，回购专用证券账户股份数为 5,363,900 股，因公司所持有的本公司股份没有表决权，故此次股东大会有表决权的股份总数为 463,407,375 股。 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，公司董事长梁耀铭先生主持，本次会议的召集、召 开及表决形式均符合《公司法》及《公司章程》的规定。 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 1、出席会议的股东和代理人人数 56 2、出席会议的股东所持有表决权的股份总数（股） 288,358,86 ...

Investment Rating - The investment rating for the company is "Buy" [1][4][12] Core Views - The company achieved a revenue of 8.54 billion with a year-on-year decline of 44.82% in 2023, primarily due to reduced demand for COVID-19 testing services. However, the core medical testing business showed a same-caliber growth of 15% [1][5][12] - The company is focusing on enhancing its organizational structure and operational efficiency to improve competitiveness and resilience in a changing market environment [1][12] - The company has maintained a strong cash flow from operating activities, with a net cash flow of 1.23 billion, representing 191% of net profit [11][12] Financial Performance - In 2023, the company reported a net profit of 643 million, down 76.64% year-on-year, with a net profit margin of 4.3%, a decrease of 10.9 percentage points [1][9][14] - The gross profit margin for 2023 was 36.5%, down 6.6 percentage points, with increases in sales, management, and R&D expense ratios [9][10] - The company expects to recover its profitability as operational efficiency measures take effect, with projected net profits for 2024-2026 at 869 million, 1.08 billion, and 1.32 billion, respectively [12][14] Business Segments - The core medical testing revenue reached 7.73 billion in 2023, with a same-caliber growth of 15.35%, driven by significant demand in infectious diseases, neurological disorders, and cancer diagnostics [1][8][12] - The company launched 412 new projects in 2023, contributing to its innovation-driven growth strategy, with notable performance in high-end testing projects [12][14] Market Position - The company is positioned as a leader in the third-party medical testing sector, benefiting from cost advantages and scale effects, while continuously enhancing its market share in line with policy trends [12][14] - The current stock price corresponds to a price-to-earnings ratio of 19, 16, and 13 for the years 2024-2026, indicating a favorable valuation compared to industry peers [12][14]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 15% compared to the CSI 300 index in the next six months [1][8]. Core Insights - The company's short-term performance has been negatively impacted by external factors and impairment provisions, but future growth remains promising [3][4]. - In 2023, the company achieved a revenue of 85.40 billion RMB, a year-on-year decrease of 44.82%, primarily due to reduced testing demand related to public health events [2][4]. - The company's net profit for 2023 was 6.43 billion RMB, down 76.64% year-on-year, with a non-recurring net profit of 3.65 billion RMB, reflecting an 86.53% decline [2][4]. - The company plans to distribute a cash dividend of 0.88 RMB per share to all shareholders, which represents 77.56% of the net profit attributable to shareholders [2][4]. Financial Performance Summary - The company’s revenue for 2024 is projected to be 95.17 billion RMB, with a year-on-year growth rate of 11% [4][5]. - The net profit for 2024 is expected to be 7.33 billion RMB, reflecting a growth rate of 14% [4][5]. - The company’s gross profit margin decreased by 6.65 percentage points to 36.48% in 2023, while the overall net profit margin dropped by 10.91 percentage points to 7.46% [2][4]. - The company’s accounts receivable decreased from 70.25 billion RMB in 2022 to 53.35 billion RMB in 2023, indicating improved cash collection trends [3][4]. Business Growth and Strategy - The company’s core business is showing signs of recovery, with regular medical diagnostic service revenue increasing by 15.35% year-on-year to 77.26 billion RMB in 2023 [2][4]. - Significant growth was observed in key disease areas, with diagnostic services for neurological and psychiatric diseases growing by 30.32%, infectious diseases by 49.74%, and cardiovascular and endocrine diseases by 28.78% [2][4]. - The company has established 49 medical laboratories in mainland China and Hong Kong, with a focus on high-end market development, as evidenced by a 4.73 percentage point increase in revenue from tertiary hospital clients [2][4].

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company's revenue from routine medical testing reached 7.726 billion yuan in 2023, with a year-on-year growth of 15.35%. The proportion of revenue from tertiary hospitals increased significantly to 43.13%, up by 4.73 percentage points [6][7] - The company aims to improve profitability through cost reduction and efficiency enhancement, with a net profit margin of 7.46% in 2023, down by 10.91 percentage points year-on-year. The company reduced its workforce by 2,825 employees, a decrease of 19.60% year-on-year, which is expected to positively impact profitability in 2024 [6][7] Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 8.540 billion yuan, a decrease of 44.82% year-on-year. The net profit attributable to shareholders was 643 million yuan, down 76.64% year-on-year. The operating cash flow was 1.231 billion yuan, down 36.81% year-on-year [5][8] - For Q1 2024, the company reported a revenue of 1.841 billion yuan, a year-on-year decrease of 13.05%, with a net profit of -19 million yuan [5][8] Revenue Breakdown - The company developed 412 new projects in 2023, contributing 6.38 billion yuan to total revenue, accounting for 7.47% of total revenue. Notable growth was seen in various diagnostic areas, including a 398.97% increase in revenue from infection tNGS series and a 525.35% increase in single-gene carrier screening [6][7] Profitability Outlook - The company is expected to improve its profitability in 2024 due to the gradual weakening of impairment losses and cost pressures from past expansions. The forecasted EPS for 2024-2026 is 1.80, 2.33, and 3.03 yuan, respectively, with corresponding P/E ratios of 22.0, 17.0, and 13.1 times [8][9]

证券代码：603882 证券简称：金域医学 公告编号：2024-041 本次业绩说明会以视频录播结合网络文字互动方式召开，公司将针对 2023 年度及 2024 年第一季度经营成果及财务指标的具体情况与投资者进行互动交流 和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 1 会议召开时间：2024 年 5 月 16 日(星期四)15:00-16:00 会议召开地点：价值在线（www.ir-online.cn），投资者可访问网址 ht tps://eseb.cn/1ekC7X8LSEg 参会。 会议召开方式：视频录播结合网络文字互动 广州金域医学检验集团股份有限公司 关于召开 2023 年度暨 2024 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 问题征集方式：投资者可于 2024 年 5 月 15 日中午 12:00 前访问网址 h ttps://eseb.cn/1ekC7X8LSEg 进行会前提问，或将相关问题通过电子邮件 的形式发送至公司董事会办公室邮箱：si ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 58.11 CNY, down from the previous target of 74.90 CNY [1][4]. Core Views - The report indicates that the company's short-term performance is under pressure but anticipates a recovery in profitability due to the rebound in routine medical testing demand, cost reduction, and efficiency improvements [1][4]. - The company achieved a revenue of 8.54 billion CNY in 2023, a decrease of 45% year-on-year, with a net profit attributable to shareholders of 643 million CNY, down 76.63% [1][4]. - The report maintains a "Buy" rating, reflecting expectations for gradual recovery in profitability as routine medical testing demand rebounds and operational efficiencies are realized [1][4]. Summary by Sections Financial Performance - The company reported a revenue of 8.54 billion CNY in 2023, a decline of 45% compared to the previous year, with a net profit of 643 million CNY, down 76.63% [1][4]. - The first quarter of 2024 saw a revenue of 1.84 billion CNY, a decrease of 13.05% year-on-year, with a net profit of 19 million CNY, indicating a transition to a loss [1][4]. Earnings Forecast - The forecast for EPS (Earnings Per Share) is adjusted to 1.49 CNY for 2024, 2.04 CNY for 2025, and 2.55 CNY for 2026, reflecting a downward revision from previous estimates [1][4]. - The report anticipates a gradual recovery in earnings driven by the resumption of routine medical testing and improved operational efficiency [1][4]. Market Position and Strategy - The company is positioned as a leading player in the third-party medical testing industry in China, with a focus on digital transformation and cost reduction strategies [1][4]. - The report highlights the company's ongoing efforts to enhance service efficiency and customer experience through the establishment of national disease alliances and precision medicine centers [1][4].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603882 证券简称：金域医学 公告编号：2024-040 广州金域医学检验集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 | 回购方案首次披露日 | 2024/4/16 | | | --- | --- | --- | | 回购方案实施期限 | 自董事会审议通过后 12 个月内 | | | 预计回购金额 | 5,000 万元 | 万元~5,000 | | 回购用途 | √用于员工持股计划或股权激励 | □减少注册资本 | | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 705,000 | 股 | | 累计已回购股数占总股本比例 | 0.1504% | | | 累计已回购金额 | 2,903.79 | 万元 | | 实际回购价格区间 | 38.05 元/股 | 元/股~46.97 | 2024 年 4 月 16 日，公司实施首次回购，截至 2024 年 4 月 30 日，本次回购方 ...

证券代码：603882 证券简称：金域医学 公告编号：2024-039 公司股东圣域钫为梁耀铭先生控制的合伙企业，直接持有公司无限售流通 股股份 21,000,000 股，占公司总股本的 4.48%。本次补充质押股份 1,000,000 股，占圣域钫直接持有公司股份数的 4.76%，占公司总股本的 0.21%。 本次股份补充质押后，公司控股股东、实际控制人梁耀铭先生及其一致行 动人严婷女士、曾湛文先生以及梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及 锐致累计质押 23,840,000 股，占其持有公司股份总数的 14.45%，占公司总股 本的 5.09%。 一、上市公司股份补充质押 广州金域医学检验集团股份有限公司（以下简称"公司"）控股股东、实际 控制人梁耀铭先生于 2023 年 4 月 4 日、2023 年 11 月 7 日及 2024 年 2 月 27 日 办理了部分股份质押手续（公告编号：2023-007、2023-057 及 2024-018）。近日 公司接到梁耀铭先生的通知，获悉梁耀铭先生于 2024 年 4 月 29 日办理了股份补 充质押手续。 公司股东广州市圣域钫投资咨询合伙企业（有限合伙）（以 ...

Investment Rating - The report maintains a "Recommended" rating for the company Jin Yu Medical (金域医学) [1][2]. Core Views - The company has experienced significant revenue and profit declines due to changes in industry conditions and impairment provisions, but the long-term outlook remains positive [1][2]. - The company achieved a revenue of 8.54 billion yuan in 2023, a decrease of 44.82%, with a net profit of 643 million yuan, down 76.64% [1]. - The first quarter of 2024 saw a revenue of 1.84 billion yuan, a decline of 13.05%, and a net loss of 19 million yuan [1]. Financial Performance Summary - In 2023, the company reported a significant drop in revenue and profits, primarily due to reduced demand for testing services related to public health events [1]. - The company’s regular medical testing business generated revenue of 7.73 billion yuan in 2023, with a year-on-year growth of 15.35% [1]. - The company completed the development of 412 new projects in 2023, contributing 638 million yuan in revenue [1]. Future Outlook - The revenue target for 2024 has been adjusted to 9.3 billion yuan, with projected net profits of 981 million yuan, reflecting a growth of 52.52% year-on-year [2][3]. - The company is focusing on digital transformation to improve operational efficiency and profitability, leveraging big data and automation technologies [1]. - The report anticipates that the industry will see a consolidation phase post-competition, benefiting leading companies like Jin Yu Medical [1].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's revenue for 2023 was 8.54 billion yuan, a year-on-year decrease of 44.82%, with a net profit attributable to shareholders of 0.6438 billion yuan, down 76.64% year-on-year [4][6] - The decline in performance is attributed to a significant reduction in COVID-19 testing demand, increased credit impairment losses, and a slowdown in the growth of routine medical testing business [4][6] - Despite the overall decline, the routine medical testing business showed a robust growth of 15.35% year-on-year, with revenues reaching 7.73 billion yuan [4][6] - The company has developed 412 new projects in 2023, contributing 0.638 billion yuan in revenue, with notable growth in specific diagnostic areas [4][6] Financial Summary - The company's main revenue for 2022 was 15.48 billion yuan, with a net profit of 2.75 billion yuan [3][7] - For 2024, the expected revenue is 9.20 billion yuan, with a projected net profit of 0.663 billion yuan [3][7] - The earnings per share (EPS) for 2024 is estimated at 1.41 yuan, with a price-to-earnings (P/E) ratio of 26.94 [3][7] - The company’s overall gross margin decreased by 6.65 percentage points to 36.48% in 2023, influenced by industry competition and policy changes [4][6] Future Outlook - The company is expected to recover and achieve net profits of 1.06 billion yuan and 1.43 billion yuan in 2025 and 2026, respectively [6][7] - The report suggests a reasonable target price of 45.40 to 56.75 yuan per share for 2025, based on a P/E ratio of 20-25 times [6][7]